Halma Plc acquires Lamidey Noury, enhancing minimally invasive surgical solutions

Halma plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Halma Plc (LON:HLMA), the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for everyone, every day, has announced that it has acquired Lamidey Noury Medical. 

Founded in 1947 and headquartered close to Paris, Lamidey Noury manufactures advanced electrosurgical and associated energy devices which are used in minimally invasive urology, gynaecology, and general surgery. Its products are sold to healthcare providers in over 60 countries. 

The cash consideration for Lamidey Noury is €50m (approximately £42m), on a cash- and debt-free basis, to be funded from Halma’s existing facilities. 

Lamidey Noury’s unaudited revenue for the 12 months to October 2024 was €13.6m (approximately £11.4m), with an EBIT margin above the upper end of Halma’s target range of 19-23%. Lamidey Noury will be a standalone company within Halma’s Healthcare Sector, led by its current management team. 

Marc Ronchetti, Group Chief Executive of Halma, commented: 

“Lamidey Noury is an exciting acquisition which will bring new minimally invasive surgical product capabilities to our Healthcare Sector. Its advanced products improve patient outcomes and the efficiency of healthcare providers in treating the increasing incidence of urological and gynaecological disease. It is adjacent to our existing presence in diagnosis and biopsy devices for these diseases through Rovers Medical Devices and IZI Medical. We are delighted to welcome Lamidey Noury to Halma and look forward to supporting its development as it continues to scale its business globally.” 

Guillaume Noury, President of Lamidey Noury said: 

“Joining Halma is an exciting opportunity for us. Leveraging Halma’s expertise, resources, and global reach will accelerate our growth and innovation. We are confident in our ability to continue delivering high-quality surgical tools to our customers worldwide, while providing new opportunities for our employees and stakeholders. Together, we will continue improving patient outcomes and driving excellence in healthcare.” 

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Halma plc (LON:HLMA) reports strong half-year results, announcing a 7% interim dividend increase, boosting shareholder returns in 2024.
    Halma plc (LON:HLMA) has released its full year results for the year ending 31 March 2024. Explore the financial details and dividend information here.
    Halma plc (LON: HLMA) releases its trading update for the financial year, showing strong growth and strategic investments. Full year results expected on 13 June 2024.
    Halma plc has appointed Giles Kerr as an independent non-executive Director, bringing valuable insights from his extensive experience in life sciences and technology sectors. Roy Twite will step down as a Director on 7 June 2024.

      Search

      Search